We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





Identification of Promising Inhibitors Could Lead to New Antiviral Drugs to Treat COVID-19 Infections

By HospiMedica International staff writers
Posted on 16 Aug 2021
Print article
Illustration
Illustration
A team of scientists has identified promising inhibitors that could lead to new antiviral drugs to treat COVID-19 outbreaks among unvaccinated or undervaccinated populations.

Using the Canadian Light Source (CLS), a national research facility at the University of Saskatchewan (Saskatoon, Canada), researchers from the University of Alberta (Edmonton, Canada) isolated promising inhibitors that could be used to treat COVID-19 infections. The rapid development of safe and effective COVID-19 vaccines has been a major step forward in helping bring the pandemic under control. But with the rise of variants and an uneven global distribution of vaccines, COVID-19 is a disease that will have to be managed for some time. Antiviral drugs that target the way the virus replicates may be the best option for treating outbreaks of COVID-19 in unvaccinated and undervaccinated populations.

The scientists used the synchrotron at CLS remotely during the facility’s special COVID-19 call for proposals, an initiative created to support research to help fight the pandemic. The synchrotron creates light millions of times brighter than the sun that helps researchers to find very detailed information about their samples. The scientists used the CMCF beamline at the CLS to search for molecules that could stop SARS-CoV-2 - the virus that causes COVID-19 - from replicating inside human cells. The team found inhibitors that target a special kind of protein called a protease, which is used by the virus to make more copies of itself. Proteases act like an axe and help the virus chop up large proteins. Without this protein, the virus would be unable to multiply and harm human health.

While COVID-19 and its cousins SARS and MERS cause serious respiratory diseases, coronaviruses are also responsible for a wide range of illnesses in humans and animals. The proteases are very similar among the different coronaviruses, according to the researchers. Over the past decade, oral antiviral medication has become more accessible to patients in need. There are oral protease inhibitors that treat and manage symptoms for diseases like HIV and hepatitis C. The research team is aiming to help make SARS-CoV-2 inhibitors available in a pill form, which would make it easier to treat COVID-19.

“It's likely that any antiviral that is developed for one coronavirus would also be a broad specificity inhibitor that could treat a variety of coronavirus infections, including those found in animals,” said Joanne Lemieux, a professor in the U of A’s Faculty of Medicine & Dentistry. “With many people working around the world developing antivirals targeting proteases, there is very likely to be one or more antivirals on the market. This would enable ease of accessibility for people around the world, especially in regions or populations where vaccines are not an option.”

Related Links:
University of Saskatchewan
University of Alberta


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
X-Ray Detector
FDR-D-EVO III

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.